Wells Fargo keeps an Equal Weight rating and $170 price target on Johnson & Johnson, saying the company has delivered a “solid” Q2 result while also noting that its implied growth acceleration for the second half of the year “seems “achievable”. On the earnings call, Johnson & Johnson management also called out the likelihood of beating the upper end of Innovative Medicine sales CAGR of 5%-7% set at the 2023 investor day, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson’s Earnings Call Highlights Growth and Challenges
- Johnson & Johnson’s Strong Financial Performance and Strategic Positioning Justifies Buy Rating
- Cautious Optimism: Johnson & Johnson’s Strong Performance and Future Prospects Amid Legal Uncertainties
- Johnson & Johnson: Hold Rating Amid Mixed Signals and Uncertainties
- Johnson & Johnson: Balancing Strong Growth Projections with Uncertainties – Hold Rating Maintained